株式会社理研ジェネシス News Releases

AmoyDx® Lung Cancer Multi-gene PCR Panel" Receives Additional Approval for Irresectable, Advanced/Recurrent Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation, for Use with Rybrevant® or Livribif® in Combination with Chemotherapy

Riken Genesis Co., Ltd. announced on April 28, 2026, that its in vitro diagnostic "AmoyDx® Lung Canc… · 2026-05-01

AmoyDx® Lung Cancer Multi-gene PCR Panel" Receives Additional Approval for Irresectable, Advanced/Recurrent Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation, for Use with Rybrevant® or Livribif® in Combination with Chemotherapy

Riken Genesis Co., Ltd. announced on April 28, 2026, that its in vitro diagnostic "AmoyDx® Lung Canc… · 2026-05-01

AmoyDx® Lung Cancer Multi-gene PCR Panel Approved as Cross-sectional Companion Diagnostic for EGFR Gene Mutations in Non-Small Cell Lung Cancer

Riken Genesis Co., Ltd. announced that on April 28, 2026, it obtained a partial change approval for … · 2026-05-01

AmoyDx® Lung Cancer Multi-gene PCR Panel Approved as Cross-sectional Companion Diagnostic for EGFR Gene Mutations in Non-Small Cell Lung Cancer

Riken Genesis Co., Ltd. announced that on April 28, 2026, it obtained a partial change approval for … · 2026-05-01